Pipeline

A diverse pipeline of investigational TransCon-based product candidates designed to make a meaningful difference for patients

A diverse pipeline of investigational TransCon-based product candidates designed to make a meaningful difference for patients

Our pipeline of innovative new therapies is driven by the flexibility of our TransCon technologies and our aim to improve patients' lives. Ascendis and its partners have multiple prodrug therapies in development. Each product candidate is unique and designed to be a best-in-class therapy.

Endocrinology Rare Diseases1

Phase 1
Phase 2
Phase 3
TransCon hGH
Pediatric GHD
Japan1
Phase 3
Adult GHD
Global2
Phase 3
Turner Syndrome
U.S.3
Phase 2
TransCon PTH
Adult Hypoparathyroidism
U.S. & Europe4
Phase 3
Adult Hypoparathyroidism
Japan5
Phase 3
TransCon CNP
Achondroplasia
Global6
Phase 2

Oncology

Phase 1
Phase 2
Phase 3
TransCon IL-2 β/γ
Solid Tumors
Systemic8
Phase 2

1Japanese riGHt Trial
2 Global foresiGHt Trial
3New Insights Trial
4NDA submitted to the FDA; PDUFA action date April 30, 2023, EU MAA submitted November 2022, decision anticipated Q4 2023
5Japanese PaTHway Japan Trial
6Global ApproaCH Trial
7transcendIT-101 Trial. Includes four indication-specific cohorts currently enrolling patients.
8IL-βelieγe Trial

Explore

You are about to access www.ascendispharma.us, which includes information intended for U.S. residents only. Click below to confirm.

CONFIRM DENY

Are you a U.S. resident?

If so, please confirm below to proceed to our U.S. website. If not, continue to our global website.

GO
(U.S. residents only) STAY
(Global)

You are about to access www.ascendispharma.us, which includes information intended for U.S. residents only. Click below to confirm.

CONFIRM DENY

You are about to access www.ascendispharma.us, which includes information intended for U.S. residents only. Click below to confirm.

GO CANEL